HILLSBOROUGH – Hillsborough-based Tellus Therapeutics, which is developing compounds from human breast milk to treat brain injuries in premature infants, has raised $75,000 in a debt round, according to a regulatory filing.
Tellus Therapeutics is developing compounds identified in human breast milk to treat white-matter brain injury in premature infants.
Tellus won the early stage company shootout at the 2018 SEBIO investor and partnering event in Atlanta.
The company was founded in 2018 to translate research by Duke neonatologist and stem cell biologist, Eric Benner, MD/PhD, into a treatment for babies born at risk for brain injury.
One in 10 babies is born premature and at significant risk for white matter (myelin) injury and subsequent life-long cognitive and neurological impairments, such as cerebral palsy.
